HRP20080648A2 - Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins - Google Patents

Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins

Info

Publication number
HRP20080648A2
HRP20080648A2 HR20080648A HRP20080648A HRP20080648A2 HR P20080648 A2 HRP20080648 A2 HR P20080648A2 HR 20080648 A HR20080648 A HR 20080648A HR P20080648 A HRP20080648 A HR P20080648A HR P20080648 A2 HRP20080648 A2 HR P20080648A2
Authority
HR
Croatia
Prior art keywords
nmdar
fusion peptide
interacting proteins
component
inhibiting interaction
Prior art date
Application number
HR20080648A
Other languages
English (en)
Croatian (hr)
Inventor
Meyer Thomas
Original Assignee
Xigen S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen S.A. filed Critical Xigen S.A.
Publication of HRP20080648A2 publication Critical patent/HRP20080648A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HR20080648A 2006-07-31 2008-12-12 Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins HRP20080648A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06015911A EP1884521A1 (en) 2006-07-31 2006-07-31 Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
PCT/EP2007/006619 WO2008014917A1 (en) 2006-07-31 2007-07-25 Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins

Publications (1)

Publication Number Publication Date
HRP20080648A2 true HRP20080648A2 (en) 2009-02-28

Family

ID=37084687

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080648A HRP20080648A2 (en) 2006-07-31 2008-12-12 Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins

Country Status (15)

Country Link
US (1) US20090281036A1 (xx)
EP (2) EP1884521A1 (xx)
JP (1) JP2009545543A (xx)
KR (1) KR20090033868A (xx)
CN (1) CN101490081A (xx)
AT (1) ATE509948T1 (xx)
AU (1) AU2007280717A1 (xx)
BR (1) BRPI0714783A2 (xx)
CA (1) CA2653438A1 (xx)
HR (1) HRP20080648A2 (xx)
IL (1) IL195536A0 (xx)
MX (1) MX2009001095A (xx)
NO (1) NO20090875L (xx)
RU (1) RU2009106710A (xx)
WO (1) WO2008014917A1 (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2804424T3 (es) 2006-07-11 2021-02-08 Nono Inc Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre
GB0804496D0 (en) * 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
EP2307035B1 (en) * 2008-05-16 2013-12-04 NoNO Inc. Use of an inhibitor of psd-95treatment for epilepsy
JP5801197B2 (ja) 2008-09-03 2015-10-28 ノノ インコーポレイテッド 痛みの治療に関する薬剤及び方法
PT2440231T (pt) * 2009-06-10 2020-01-08 Nono Inc Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos
PL2440230T3 (pl) * 2009-06-10 2021-06-14 Nono Inc. Schematy leczenia do leczenia choroby neurologicznej
EP2616094B1 (en) 2010-08-12 2017-11-08 NoNO Inc. Treatment of penetrative injury to the brain
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012158624A2 (en) 2011-05-13 2012-11-22 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of mitochondrial fission and methods of use thereof
KR102296106B1 (ko) 2011-06-24 2021-08-30 노노 인코포레이티드 허혈에 대한 psd-95 억제제와의 조합 요법
US9579358B2 (en) 2011-10-10 2017-02-28 Lancaster University Business Enterprises Limited Compositions for binding to amyloid proteins
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
DK2800575T3 (da) * 2011-12-13 2019-07-01 Nono Inc Behandling af subarachnoidalblødning og iskæmi
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
PL2925338T3 (pl) * 2012-11-28 2019-11-29 Nono Inc Liofilizowana formulacja TAT-NR2B9C
US20140296164A1 (en) * 2013-03-29 2014-10-02 Calista Therapeutics, Inc. Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
PL3013353T3 (pl) 2013-06-26 2021-09-20 Xigen Inflammation Ltd. Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza
JP6495270B2 (ja) 2013-10-30 2019-04-03 ザ ユニバーシティ オブ ウェスタン オーストラリア 神経保護ペプチドを含有する医薬組成物
CN103804500B (zh) * 2014-01-22 2015-12-30 广州军区广州总医院 用于治疗慢性疼痛的多肽
EP3119415A4 (en) * 2014-03-07 2017-11-29 The Arizona Board of Regents on behalf of the University of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
CN103936838B (zh) * 2014-04-10 2015-10-28 武汉启瑞科技发展有限公司 小分子多肽TAT-p53DM及其在制备治疗或预防缺血性卒中药物中的应用
JP6707469B2 (ja) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
LT3149048T (lt) 2014-05-28 2020-05-11 Nono Inc. Tat-nr2b9c chlorido druska
US20170253643A1 (en) * 2014-09-02 2017-09-07 Tokyo University Of Science Foundation Centrally-Acting Peptide Derivative, and Pharmaceutical Composition
CN104650242A (zh) * 2015-01-13 2015-05-27 河南科技大学 一种融合多肽及其制备方法和应用
JP6958913B2 (ja) 2015-11-06 2021-11-02 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 心停止の処置のためのペプチドおよび方法
JP6818871B2 (ja) * 2016-04-27 2021-01-20 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド
US11208446B2 (en) * 2016-11-01 2021-12-28 Memorial Sloan Kettering Cancer Cenier Agents and methods for treating CBP-dependent cancers
CN110049994B (zh) * 2016-12-08 2023-05-02 拜西欧斯（北京）生物技术有限公司 一种缀合物及其应用
WO2018184059A1 (en) * 2017-04-02 2018-10-11 Interk Peptide Therapeutics Limited Compositions and methods for prophylaxis or treatment of pain
EP3650460A4 (en) 2017-07-05 2021-03-17 Biocells (Beijing) Biotech Co., Ltd. PHARMACEUTICAL SALT OF A POLYPEPTID AND ITS USES
CN110799547B (zh) * 2017-07-05 2023-02-28 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
JP2022549057A (ja) 2019-07-11 2022-11-24 厦▲門▼大学 分子の細胞内送達のための複合体
EP4086275A4 (en) 2019-12-31 2024-04-17 Univ Xiamen MULTIMERIZATION DELIVERY SYSTEM FOR INTRACELLULAR DELIVERY OF MOLECULES
EP4087880A4 (en) * 2020-01-09 2024-01-24 Nono Inc PLASMIN RESISTANT PEPTIDES FOR THE TREATMENT OF STROKE AND RELATED CONDITIONS
CN114539358B (zh) * 2020-11-19 2023-09-15 中国科学院大连化学物理研究所 一种多肽及制备方法与应用
CN112853559B (zh) * 2020-12-31 2021-10-08 盐城师范学院 一种基于环锭纺纱线质量的工序约束嵌套控制系统及方法
CN113735938A (zh) * 2021-07-30 2021-12-03 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7410998A (en) * 1996-11-26 1998-06-22 Johns Hopkins University, The Ligand detection system and methods of use thereof
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
CA2505479A1 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons

Also Published As

Publication number Publication date
MX2009001095A (es) 2009-02-10
EP2046821B1 (en) 2011-05-18
US20090281036A1 (en) 2009-11-12
EP1884521A1 (en) 2008-02-06
EP2046821A1 (en) 2009-04-15
CA2653438A1 (en) 2008-02-07
BRPI0714783A2 (pt) 2013-07-30
KR20090033868A (ko) 2009-04-06
NO20090875L (no) 2009-02-25
CN101490081A (zh) 2009-07-22
ATE509948T1 (de) 2011-06-15
JP2009545543A (ja) 2009-12-24
WO2008014917A1 (en) 2008-02-07
RU2009106710A (ru) 2010-09-10
IL195536A0 (en) 2011-08-01
AU2007280717A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
IL195536A0 (en) Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
BRPI0809366B8 (pt) polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
RS50966B (sr) Agonisti pyy i njihova upotreba
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
MX2009006199A (es) Formulacion parenteral de anticuerpos abeta.
IL169820A0 (en) Amino acids with affinity for the alpha-2-delta-protein
EP2617431A3 (en) Polypeptide inhibitors of HSP27 kinase and uses therefor
SI1848458T1 (sl) Uporaba aktiviranega polimera za ločevanje proteina in polipeptidnih multimerov
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
WO2006042745A3 (de) Chemisch modifizierte iapp - peptidanaloga
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
WO2005074626A3 (en) Compositions, methods and uses for a novel family of peptides
WO2008093058A3 (en) Peptides and their use
IL173764A0 (en) Amino acids with affinity for the alpha2delta-protein
IL223076A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
BRPI0505090A (pt) composição de toner
BRPI0516922A (pt) composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
WO2007047962A3 (en) Insecticides that target protein kinase a (pka)
WO2008081812A1 (ja) 抗腫瘍ペプチド及びその利用
WO2010042685A3 (en) Inhibitors of the atb(0,+) transporter and uses thereof
WO2004087054A3 (en) Methods for modulating gastric secretion using prokineticin receptor antagonists.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20100721

Year of fee payment: 4

OBST Application withdrawn